Skip Ribbon Commands
Skip to main content

News Release


The Brussels based biopharmaceutical company UCB entrusts the management of its real estate portfolio to JLL

Brussels, 4 November 2014 - Global biopharmaceutical company UCB has renewed a three year global real estate services agreement with JLL across a portfolio of 310.000 m² in 40 countries. 

This agreement expands on an existing mandate awarded in 2011 where JLL was appointed​ to provide lease administration, transaction management, and real estate advisory services. New services added include financial management, and project and development services (P&DS). TETRIS, JLL's design, fit-out and refurbishment specialist have also been appointed to work on multiple occupier projects.

​​"JLL have helped us gain clarity across our global real estate portfolio. This knowledge has permitted us to anticipate lease events and start taking sound and strategic decisions in line with our future business needs. Comparing our various local situations with relevant market intelligence has given us an unprecedented edge in our real estate portfolio management." said Jean-Christophe Donck, Vice-President Site Facilities & Workplace Development, UCB.​​​​​

"Since 2011 when this client relationship started, we have focused on providing the most efficient corporate solutions framework for UCB's global real estate portfolio. We have already generated €9.5 million in cost savings across Tokyo, France, Spain, Portugal, The Netherlands and Italy. The newly extended contract scope means that we will further build on this and continuously enhance real estate solutions supported by robus​t project management services." said Eric Orban, UCB Global Client Manager, JLL Corporate Solutions.

Corporate Solutions by JLL (​) prov​​ides support services to companies that use professional areas: the management of the property portfolio, research for new sites, renegotiatin​g financial terms of the lease, setting up new offices or from a current office.

Headquartered in Brussels (Belgium), UCB ( is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8500 people in approximately 40 countries, the company generated revenue of € 3.4 billion in 2013. UCB is listed on Euronext Brussels (symbol: UCB). The largest individual project undertaken to date was the relocation of UCB's Japanese 2,650 m² offices in Tokyo (Japan).